研究显示，BRAF V600E 突变导致肿瘤细胞激活 MAPK 信号通路，进而快速增殖和转移，使得患者的生存预期显著降低 [2] 。此外，BRAF V600E 突变患者通常对 ...

转移性结直肠癌（mCRC）患者中约8%~15%存在BRAF基因突变，BRAFV600E是最常见的突变形式之一。BRAFV600E突变型的mCRC患者预后差、总生存期短。Encorafenib是一种高选择性的ATP竞争性小分子BRAF抑制剂，西妥昔单抗 ...

Pfizer PFE announced positive top-line results from the progression-free survival (PFS) analysis of a late-stage study of its ...

BRAF V600E-mutant metastatic CRC is associated with poor clinical outcomes, with a median overall survival of 17 months. Factors influencing overall survival include metastasectomy and ECOG ...

BRAF V600E mutations are common in different tumor types (more frequently in melanomas, colon and thyroid carcinomas). BRAF Alterations in Brain Tumors: Different Diagnostic Relevance of BRAF ...

For patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), encorafenib + cetuximab (EC) plus standard ch ...

The trial enrolled patients who were at least 16 years of age with previously untreated BRAF V600E-mutant mCRC. Patients were randomized equally to one of three treatment arms: SOC chemotherapy ...

Pfizer (PFE) announced positive topline results from the progression-free survival – PFS – analysis of the Phase 3 BREAKWATER study of Braftovi ...

“Despite the high unmet need in this patient population, prior to the recent encorafenib combination regimen approval, there were no approved biomarker-driven therapies indicated for people with ...